Preferences help
enabled [disable] Abstract
Number of results
2018 | 107 | 84-96
Article title

Oral cavity diseases in HIV infected patients

Title variants
Languages of publication
Oral cavity lesions are amongst the earliest manifestations of HIV-infection. Thorough examination of oral cavity as well as awareness of associations between specific symptoms and HIV-infection can lead to early diagnosis of this life-long disease. Consequently, early diagnosis of HIV infection allows for prompt introduction of antiretroviral therapy allowing to improve patients’ quality of life, their life expectancy but also reducing the risk of transmission. Therefore, raising awareness on oral cavity disorders suggestive of HIV-infection among general physicians and dentists is of a great importance. In this article we described the most common oral cavity manifestations associated with HIV infection including: oral candidiasis, hairy leukoplakia and Kaposi’s sarcoma in detail.
Physical description
  • Department of Infectious Diseases and Hepatology in Bytom, Medical University of Silesia in Katowice, Poland
  • Department of Infectious Diseases and Hepatology in Bytom, Medical University of Silesia in Katowice, Poland
  • Department of Infectious Diseases and Hepatology in Bytom, Medical University of Silesia in Katowice, Poland
  • Department of Infectious Diseases and Hepatology in Bytom, Medical University of Silesia in Katowice, Poland
  • Department of Infectious Diseases and Hepatology in Bytom, Medical University of Silesia in Katowice, Poland
  • [1] G.K. Nikolopoulos, E.G Kostaki, D. Paraskevis, Overview of HIV molecular epidemiology among People who Inject Drugs in Europe and Asia. Infect Genet Evol. 46 (2016) 256–268.
  • [2] 2017 HIV global statistics.
  • [3] P.B. Pavlinac, S.E. Hawes, G. S. Gottlieb, A. Gaye, C. F. N'Diaye, C.W. Critchlow, P.S. Sow, Q. Feng, and N. B. Kiviat, HIV shedding in the oral cavity: an assessment of HIV type, immunovirologic, demographic and oral factors. Sex Transm Infect. 88(1) (2012) 45–50.
  • [4] M.S. Cohen et al., Prevention of HIV-1 Infection with Early Antiretroviral Therapy. New Eng J Med. 365 (2011) 493-505.
  • [5] A.B. Bhatti, M. Usman, V. Kandi, Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral Therapy. Cureus. 8(3) (2016).
  • [6] S . Lucas, A.M. Nelson, HIV and the spectrum of human disease. J Pathol. 235(2) (2015) 229-41.
  • [7] M.S. Richard, E.D Mokotoff et all,. Revised Surveillance Case Definition for HIV Infection — United States, 2014. Recommendations and Reports: Morbidity and Mortality Weekly Report. Recommendations and reports. 63 (2014) 1-10.
  • [8] About HIV/AIDS. 23.06.2018
  • [9] D. Greenspan, E. Komaroff, M. Redford, J.A. Phelan, M. Navazesh, M.E. Alves, H. Kamrath, R. Mulligan, C.E. Barr, J.S. Greenspan Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr. 25(1) (2000) 44-50
  • [10] Mocroft, J.D. Lundgren M.L. Sabin, A. d’ArminioMonforte, N. Brockmeyer, J.C. Casabona, A. Castagna, D. Costagliola, Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 10(9) (2013).
  • [11] M. Battergay, U. Fluckiger, B. Hirschel, H. Furrer, Late presentation of HIV-infected individuals. Antivir Ther. 12(6) (2007) 841-51.
  • [12] B.L. Hønge, S. Jespersen, J. Aunsborg, High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1/2 dually infected patients in Guinea-Bissau - a cohort study from West Africa. Pan Afr Med J. 25 (40) (2016).
  • [13] Antinori, T. Coenen, D. Costagiola, N. Dedes, M. Ellefson, J. Gatell, F. Girardi, M. Johnson, O. Kirk, J. Lundgren, A. Mocroft, A. D’Arminino Monforte, A. Phillips, D. Rabem, J.K. Rockstrah, C. Sabin, A. Sönnerborg, F. De Wolf, European Late Presenter Consensus Working Group. Late presentation of HIV infection: a consensus definition. HIV Med. 12(1) (2011) 61-4.
  • [14] J.A. Fleishman, B.R. Yehig, R.D. Moore, K.A Gebo, HIV Research Network, The economic burden of late entry into medical care for patients with HIV infection. Med Care. 48(12) (2010) 1071-9.
  • [15] A.S. Bodhade, S.M. Ganvir, V.K. Hazarey, Oral manifestations of HIV infection and their correlation with CD4 count. J Oral Sci 53 (2011) 203-211
  • [16] T.O. Menezes, M.C. Rodrigues, B.M. Noguiera, S.A. Menzes, S.H.Silva, A.C. Vallinoto, Oral and systemic manifestations in HIV-1 patients. Rev Soc Bras Med Trop. 48(1) (2015) 83-6.
  • [17] L.L. Patton, Oral lesions associated with human immunodeficiency virus disease. Dent Clin North Am. 57(4) (2013) 673-98.
  • [18] A.R. Tappuni, G.J. Fleming, The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med. Oral Pathol Oral Radiol Endod. 92(6) (2001) 623-8.
  • [19] P. Frimpong, E.K. Amponsah, J. Abebrese J, S.M. Kim. Oral manifestations and their correlation to baseline CD4 count of HIV/AIDS patients in Ghana. Journal of the Korean Association of Oral and Maxillofacial Surgeons. 43(1) 2017:29-36.
  • [20] T. Maurer, M. Ponte, K. Leslie, HIV-Associated Kaposi's Sarcoma with a High CD4 Count and a Low Viral Load. N Engl J Med (2007) 1352-1353.
  • [21] C.N. John, L.X. Stephen, C.W. Joyce Africa. Is human immunodeficiency virus (HIV) stage an independent risk factor for altering the periodontal status of HIV-positive patients? A South Africans study. BMC Oral Health. (2013) 13:19.
  • [22] F. Hang, S. He, J. Jin et al. Exploring salivary microbiota in AIDS patients with different periodontal statusem Rusing 454 GS-FLX Titanium pyro sequencing. Frontiers in Cellular and Infection Microbiology. 5 (2015).
  • [23] G. Dharma, S-S. Oberoi, P. Vohra et al. Oral manifestations of HIV/AIDS in Asia: Systematic review and future research guidelines. Journal of Clinical and Experimental Dentistry. 7(3) (2015) 419-427.
  • [24] R.R. Jagganatha, R.G.R. Tuthipat, Estimation of prevalence of periodontal disease and oral lesions and their relation to CD4 counts in HIV seropositive patients on antiretroviral therapy regimen reporting at District General Hospital, Raichur. J Indian Soc Periodontol. 19(4) (2015) 435-439.
  • [25] J. Valentine, A.E. Sanders, T. Saladyanant et al. Impact of Periodontal Intervention on Local inflammation, Periodontitis and HIV Outcomes. Oral Diseases. 22(1) (2016) 87-97.
  • [26] S.E. Heron, S. Elami. HIV Infection and Compromised Mucosal Immunity: Oral Manifestations and Systemic Inflammation. Frontiers in Immunology. 8 (2017).
  • [27] D.A. Reznik, Oral Manifestations of HIV Disease. Top HIV Med. 13(5) (2016) 143-148.
  • [28] D. Williams, M. Lewis, Pathogenesis and treatment of oral candidosis. J Oral Microbiol. 3 (2011).
  • [29] G.R. Thompson, P.K. Patel, W.R. Kirkpatrick, S.D. Westbrook, D. Berg, J. Erlandsen, S.W. Redding, T.F Patterson, Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 109(4) (2010) 488-95
  • [30] S.A.A. Mousavi, G. Asadikaram, Nouzar Nakhaee, A. Izadi, Plasma Levels of IFN-γ, IL-4, IL-6 and IL-17 in HIV-Positive Patients With Oral Candidiasis. Jundishapur J Microbiol. 9(2) (2016).
  • [31] P. Shankargouda, R.S. Rao, M. Barnali, A. Sukumaran, Clinical Appearance of Oral Candida Infection and Therapeutic Strategies. Front Microbiol. 6 (2015) 1391.
  • [32] L. Xin, C. Zhao, Y. Zhi-min, H. Hong, Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. Drug Des Devel Ther. 10 (2016) 1161–1171.
  • [33] L. Coronado-Castellote, Y. Jiménez-Soriano,Clinical and microbiological diagnosis of oral candidiasis. J Clin Exp Dent. 5(5) (2013) 279–286.
  • [34] W. Nittayananta, R. Tao, L. Jiang,Y. Peng, Y. Huang, Oral innate immunity in HIV infection in HAART era. J Oral Pathol Med. 45(1) (2016) 3–8.
  • [35] A.L. Lin, D.A Johnson, C.A. Sims, K.T. Stephan, C.K. Yeh, Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 102(3) (2006) 318-24.
  • [36] P.K. Mukherjee, J. Chandra, M. Retuerto, M. Sikaroodi, R.E. Brown, R. Jurevic, R.A. Salata, M.M. Lederman, P.M. Gillevet, M.A. Ghannoum, Oral Mycobiome Analysis of HIV-Infected Patients: Identification of Pichia as an Antagonist of Opportunistic Fungi. PLoS Pathog. 10(3) (2014).
  • [37] R.N. Spalanzani, K. Mattos , L.I. Marques, P.F.D. Barros, P.I.P. Pereira, A.M.M. Paniago, R.P. Mendes, M.R.Chang, Clinical and laboratorial features of oral candidiasis in HIV-positive patients. Rev Soc Bras Med Trop. 51(3) (2018) 352-356.
  • [38] T. A. Hodgson, C.C. Rachanis, Oral fungal and bacterial infections in HIV-infected individuals: an overview in Africa. Oral Dis. 8( 2) (2002) 80-7.
  • [39] The rules of care for people with HIV. Recommendations of the Polish Scientific Society of HIV. 2018
  • [40] Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. 26.07.2018
  • [41] T. Cihlar, M. Fordyce, Current status and prospects of HIV treatment. Current Opinion in Virology, 18 (2016) 50-56.
  • [42] Mucocutaneous Candidiasis 18.10.2017
  • [43] C. Garcia-Cuesta, M-G. Sarrion-Pérez, J. V. Bagán, Current treatment of oral candidiasis: A literature review. J Clin Exp Dent 6(5) (2014) 576-582.
  • [44] M. Navazesh, R. Mulligan, J. Pogoda, D. Greenspan, M. Alves, et al., The effect of HAART on salivary microbiota in the Women's Interagency HIV Study (WIHS). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 (2005) 701–708.
  • [45] J.C. Leao, C.M.B. Riberio, A.A.T Carvahalo, C. Frezzini, S. Porter, Oral Complications of HIV disease. Clinics (Sao Paulo). 64(5) (2009) 459-470.
  • [46] Kreuter, U. Wieland, Oral hairy leukoplakia: a clinical indicator of immunosuppression. CMAJ. 183(8) (2011) 932.
  • [47] H-H. Cho, S-H. Kim, S-H. Seo, D-S. Jung, H-C. Ko, M-B. Kim, K-S. Kwon ,Oral Hairy Leukoplakia Which Occurred as a Presenting Sign of Acute Myeloid Leukemia in a Child. Ann Dermatol. 22(1) (2010) 73–76.
  • [48] B. Crasileiro, M.H.N.G. Abreu, R.A. Mesquita, Critical review of topical management of oral hairy leukoplakia. World J Clin Cases. 2(17) (2014) 253–256.
  • [49] P.H. Braz-Silva,N.P. M. de Rezende,K.L, Ortega, Macedo Santos, M.H.C.G. de Magalhães, Detection of the Epstein–Barr Virus (EBV) by In situ Hybridization as Definitive Diagnosis of Hairy Leukoplakia. Head Neck Pathol. 2(1) (2008) 19–24.
  • [50] R.A.G. Khammissa, J. Fourie, R. Chandran, J. Lemmer, L. Feller, Epstein-Barr Virus and Its Association with Oral Hairy Leukoplakia: A Short Review. Int J Dent. (2006).
  • [51] J. Webster-Cyriaque, J. Middeldrop, N. Raab-Traub, Hairy Leukoplakia: an Unusual Combination of Transforming and Permissive Epstein-Barr Virus Infections. J Virol. 74(16) (2000) 7610–7618.
  • [52] Reginald, B.Sivapathasundharam, Oral hairy leukoplakia: An exfoliative cytology study. Contemp Clin Dent. 1(1) (2010) 10–13.
  • [53] L.L. Martins, J.H.F. Rosseto, N.S. Andrade, J.B. Franco, P. H. Braz-Silva, K.L. Ortega, Diagnosis of Oral Hairy Leukoplakia: The Importance of EBV In Situ Hybridization. Int J Dent. (2017).
  • [54] S.L. Lamers, R.Rose, D.J. Nolan et al., HIV-1 Evolutionary Patterns Associated with Metastatic Kaposi’s Sarcoma during AIDS. Sarcoma. (2016).
  • [55] R.A.G Khammissa, L. Pantanowitz, L. Feller, Oral HIV-Associated Kaposi Sarcoma: A Clinical Study from the Ga-Rankuwa Area, South Africa. AIDS Research and Treatment. (2012).
  • [56] F. Ye, X Lei, S-J. Gao, Mechanisms of Kaposi’s Sarcoma-Associated Herpesvirus Latency and Reactivation. Advances in Virology. (2011).
  • [57] J.J. Hille, J. Webster-Cyriaque J, J.M. Palefski, N. Raab-Traub, Mechanisms of expression of HHV8, EBV and HPV in selected HIV-associated oral lesions. Oral Diseases. 8(2) (2002) 161–168.
  • [58] J.B. Epstein, R.J. Cabay, M. Glick, Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology. 100(5) (2005) 571–578.
  • [59] T.S. Uldrick, D. Whitby. Update on KSHV-Epidemiology, Kaposi Sarcoma Pathogenesis, and Treatment of Kaposi Sarcoma. Cancer letters. 305(2) (2011) 150-162.
  • [60] O.F. Gbabe, C.I. Okwundu, M. Dedicoat, E.E. Freeman, Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults. The Cochrane database of systematic reviews. 8 (2014).
  • [61] J.H. Campbell, A.C. Hearps, G.E. Martin, K.C. Williams, S.M. Crowe. The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS. 28(15) (2014) 2175-87.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.